CN116640143A - 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 - Google Patents

用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 Download PDF

Info

Publication number
CN116640143A
CN116640143A CN202310213936.1A CN202310213936A CN116640143A CN 116640143 A CN116640143 A CN 116640143A CN 202310213936 A CN202310213936 A CN 202310213936A CN 116640143 A CN116640143 A CN 116640143A
Authority
CN
China
Prior art keywords
alkyl
aryl
membered heteroaryl
independently
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310213936.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·梅科嫩
J·A·布特拉
黄建星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenebio Inc
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Priority to CN202310213936.1A priority Critical patent/CN116640143A/zh
Publication of CN116640143A publication Critical patent/CN116640143A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202310213936.1A 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 Pending CN116640143A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310213936.1A CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662436272P 2016-12-19 2016-12-19
CN201780086584.0A CN110382501A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
PCT/IB2017/001762 WO2018130868A1 (en) 2016-12-19 2017-12-20 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN202310213936.1A CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780086584.0A Division CN110382501A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Publications (1)

Publication Number Publication Date
CN116640143A true CN116640143A (zh) 2023-08-25

Family

ID=62557208

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310213936.1A Pending CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN201780086584.0A Pending CN110382501A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780086584.0A Pending CN110382501A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Country Status (10)

Country Link
US (2) US20180170941A1 (enExample)
EP (1) EP3555100B1 (enExample)
JP (1) JP7153938B2 (enExample)
CN (2) CN116640143A (enExample)
AU (1) AU2017393082B2 (enExample)
CA (1) CA3047684A1 (enExample)
EA (1) EA201991497A1 (enExample)
IL (1) IL267451B2 (enExample)
MX (1) MX388726B (enExample)
WO (2) WO2018130868A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MA42624A (fr) 2015-06-19 2021-04-28 Agenebio Inc Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112601749B (zh) * 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
US11485734B2 (en) 2018-10-02 2022-11-01 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)
EP4077333A4 (en) * 2019-12-19 2024-01-10 Agenebio, Inc. BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF COGNITIVE IMPAIRMENT
US20220062296A1 (en) * 2020-07-10 2022-03-03 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
AU2021304355A1 (en) * 2020-07-10 2023-03-02 Agenebio, Inc. Polymorphs of a GABA
CN113413532B (zh) * 2021-07-01 2022-03-01 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191255C (zh) * 2000-11-16 2005-03-02 弗·哈夫曼-拉罗切有限公司 作为gaba a受体调节剂的苯并二氮杂䓬衍生物
CN101044145A (zh) * 2004-10-20 2007-09-26 弗·哈夫曼-拉罗切有限公司 咪唑并－苯并二氮杂䓬衍生物
CN103327980A (zh) * 2010-11-15 2013-09-25 艾吉因生物股份有限公司 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法
CN106068256A (zh) * 2013-12-20 2016-11-02 艾吉恩生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
WO2016205739A1 (en) * 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
NL7305644A (enExample) 1972-04-20 1973-10-23
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
DK0402644T3 (da) 1989-05-19 1996-01-02 Hoechst Roussel Pharma N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (enExample) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
JP4099224B2 (ja) 1994-03-02 2008-06-11 ナームローゼ・フエンノートチヤツプ・オルガノン 舌下又はバッカル医薬組成物
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
KR100694682B1 (ko) 1999-03-03 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 4-치환 피페리딘 유도체 불화물
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CN1829804A (zh) 2002-11-22 2006-09-06 约翰斯·霍普金斯大学 治疗认知功能障碍的靶位
ATE411015T1 (de) 2003-10-22 2008-10-15 Merz Pharma Gmbh & Co Kgaa Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien
WO2006040038A1 (en) 2004-10-12 2006-04-20 F.Hoffmann-La Roche Ag Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders
CA2584757C (en) 2004-10-20 2012-07-03 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
DE602005007265D1 (de) 2004-12-14 2008-07-10 Hoffmann La Roche Tetrazyklische imidazobenzodiazepine als gaba-rezeptormodulatoren
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
WO2007019312A2 (en) 2005-08-03 2007-02-15 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
CN102223790B (zh) 2008-09-25 2015-11-25 维乌作物保护有限公司 生产聚合物纳米颗粒的方法和活性成分的制剂
JP2013516497A (ja) 2010-01-11 2013-05-13 ミスリィディオン，インク． 認知増強のための化合物と組成物、製造方法、および治療方法
SG10201509163VA (en) 2010-11-05 2015-12-30 Hoffmann La Roche Use Of Active Pharmaceutical Compounds For The Treatment Of Central Nervous System Conditions
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
US20150224094A1 (en) 2012-09-10 2015-08-13 Ophirex, Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
CN112601749B (zh) * 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
EP4077333A4 (en) * 2019-12-19 2024-01-10 Agenebio, Inc. BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF COGNITIVE IMPAIRMENT

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191255C (zh) * 2000-11-16 2005-03-02 弗·哈夫曼-拉罗切有限公司 作为gaba a受体调节剂的苯并二氮杂䓬衍生物
CN101044145A (zh) * 2004-10-20 2007-09-26 弗·哈夫曼-拉罗切有限公司 咪唑并－苯并二氮杂䓬衍生物
CN103327980A (zh) * 2010-11-15 2013-09-25 艾吉因生物股份有限公司 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法
CN106068256A (zh) * 2013-12-20 2016-11-02 艾吉恩生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
WO2016205739A1 (en) * 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUIDO ACHERMANN ET AL.,: "Discovery of the imidazo[1, 5-a][1, 2, 4]-triazolo[1, 5-d][1, 4]benzodiazepine scaffold as a novel, potent and selective GABAA α5 inverse agonist series", 《BIOORG.MED.CHEM.LETT.》, vol. 19, 4 August 2009 (2009-08-04) *
MAX GERECKE ET AL.: "New tetracyclic derivatives of imidazo-[1, 5-a][1, 4]benzodiazepines and of imidazo-[1, 5-a]thieno[3, 2-f][1, 4]diazepines", 《HETEROCYCLES》, vol. 39, 31 December 1994 (1994-12-31), XP002198330 *
MOHD.KAMIL HUSSAIN ET AL.: "Tandem C-2 functionalization-intramolecular azide-alkyne 1, 3-dipolar cycloaddtion reaction: A convenient route to highly diversified 9H-benzo[b]pyrrolo[1, 2-g][1, 2, 3]triazolo[1, 5-d][1, 4]diazepines", 《ORG.LETT》, vol. 16, 18 December 2013 (2013-12-18) *
OLIVER JONAS ET AL.,: "First in vivo testing of compounds targeting group 3 medulloblastomas using an implantable microdevice as a new paradigm for drug development", 《J BIOMED NANOTECHNOL》, vol. 12, no. 6, 30 June 2016 (2016-06-30) *

Also Published As

Publication number Publication date
EA201991497A1 (ru) 2020-01-20
CN110382501A (zh) 2019-10-25
CA3047684A1 (en) 2018-07-19
JP2020512389A (ja) 2020-04-23
NZ755287A (en) 2025-06-27
US20180170941A1 (en) 2018-06-21
IL267451B1 (en) 2023-06-01
WO2018130869A1 (en) 2018-07-19
IL267451B2 (en) 2023-10-01
MX2019007338A (es) 2019-09-19
WO2018130868A8 (en) 2019-08-08
AU2017393082B2 (en) 2022-04-21
MX388726B (es) 2025-03-20
IL267451A (en) 2019-08-29
EP3555100A4 (en) 2020-06-10
EP3555100A1 (en) 2019-10-23
US20230134844A1 (en) 2023-05-04
JP7153938B2 (ja) 2022-10-17
WO2018130868A1 (en) 2018-07-19
AU2017393082A1 (en) 2019-07-25
EP3555100B1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
CN112601749B (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN106068256B (zh) 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
US20230134844A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12024525B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40057489A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40049071B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
HK40046882A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40049071A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016541A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254362B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
HK40016046A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230171B (zh) 用於治疗认知损害的苯并二氮杂卓衍生物、组合物和方法
HK1230171A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR122023024430A2 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de défice cognitivo associado a um distúrbio do sistema nervoso central (snc)
BR112017027515B1 (pt) Derivados de benzodiazepina, composições e métodos para tratamento de défice cognitivo
BR122023024430B1 (pt) Compostos derivados de benzodiazepina, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de défice cognitivo associado a um distúrbio do sistema nervoso central (snc)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40097181

Country of ref document: HK